Global Immuno-oncology Drugs Market to Surpass US$ 60,186.2 Million by 2030, Says Coherent Market Insights (CMI)
February 22, 2023 09:30 ET
|
CMI
Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immuno-oncology drugs market is estimated to be valued at US$ 17,394.2 in 2022 and is expected to...
Immune Checkpoint Inhibitors Market Size to Surpass USD 148.1 Bn by 2030
October 29, 2022 10:00 ET
|
Precedence Research
Ottawa, Oct. 29, 2022 (GLOBE NEWSWIRE) -- The global immune checkpoint inhibitors market size was accounted at USD 31.4 billion in 2021. The immune system's task is to safeguard the body's healthy...
Global Immune Checkpoint Inhibitors Market to Surpass US$ 3,902.9 Million by 2030, Says Coherent Market Insights (CMI)
August 29, 2022 08:40 ET
|
CMI
Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is...
Immune Checkpoint Inhibitors Market is Expected to Reach $140.89 Billion by 2030: Says AMR
February 17, 2022 10:07 ET
|
Allied Market Research
Portland, OR, Feb. 17, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global immune checkpoint inhibitors market was estimated at $29.80 billion in 2020...
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
September 08, 2021 08:30 ET
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
The immunocytokines market is estimated to be worth around USD 5.4 billion by 2030, claims Roots Analysis
June 30, 2021 10:55 ET
|
Roots Analysis
London, June 30, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “Immunocytokines Market, 2021-2030” report to its list of offerings. These engineered...
AzurRx BioPharma CEO Issues Letter to Shareholders
April 15, 2021 07:30 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma CEO Issues Letter to Shareholders
January 08, 2021 09:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
January 04, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
Agreement expands AzurRx’s pipeline of targeted, non-systemic GI therapies Clinical trials to initiate in 1H’21, with potential for expedited FDA 505(b)(2) pathway for IND-approved COVID-19 and...
Immune Checkpoint Inhibitors Market to Reach $56.53 Bn by 2025
April 23, 2020 10:11 ET
|
Allied Market Research
Portland, OR, April 23, 2020 (GLOBE NEWSWIRE) -- The global Immune Checkpoint Inhibitors Market was valued at $10.56 billion in 2017 and is projected to reach $56.53 billion by 2025, registering a...